Newer avenues for the treatment of leptomeningeal carcinomatosis

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 38-44

  Meriggi, Fausto ^a   Zaniboni, Alberto ^a  

^a Fondazione Poliambulanza   (Italy)

Author keywords

Intrathecal therapy; Leptomeningeal carcinomatosis; Systemic therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTARABINE; ETOPOSIDE; GADOLINIUM; MAFOSFAMIDE; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB;

ANALGESIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BLADDER DYSFUNCTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID CULTURE; CHILDHOOD CANCER; COGNITIVE DEFECT; CONFUSION; CRANIAL NERVE; DIPLOPIA; DYSPHAGIA; HEADACHE; HEARING LOSS; HEMIPARESIS; HUMAN; LUNG CANCER; MELANOMA; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NERVE FIBER; NEUROGENIC BOWEL; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARESTHESIA; PATHOPHYSIOLOGY; PROGNOSIS; RADICULAR PAIN; SEIZURE; SENSORY DYSFUNCTION; VISUAL IMPAIRMENT; WALKING DIFFICULTY; WEAKNESS; ADULT; ANATOMY AND HISTOLOGY; CHILD; MENINGEAL CARCINOMATOSIS; MENINX; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; MENINGEAL CARCINOMATOSIS; MENINGES; NEOPLASM METASTASIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79953013477     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152411794961068     Document Type: Article

References (99)

1. Posner, J.; Chernik, N.L. Intracranial metastases from systemic cancer. Adv. Neurol., 1978, 19, 579-592.
2. Glass, J.P.; Melamed, M.; Chernik, N.L. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology, 1979, 29, 1369-1375.
3. Kaplan, J.G.; DeSouza, T.G.; Farkash, A. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J. Neurooncol., 1990, 9, 225-229.
4. Wasserstrom, W.R.; Glass, JP.; Posner, J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer, 1982, 49, 759-772.
5. Little, J.R.; Dale, A.J.; Okazaki, H. Meningeal carcinomatosis. Clinical manifestations. Arch. Neurol., 1974, 30, 138-143.
6. Jayson, G.C.; Howell, A. Carcinomatous meningitis in solid tumours. Ann. Oncol., 1996, 7, 773-786.
7. Grossman, S.A.; Krabak, US. Leptomeningeal carcinomatosis. Cancer Treat Rev., 1999, 25, 103-109.
8. Pavlidis, N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann. Oncol., 2004, 15 (Supplement 4), iv285-iv291.
9. Wagner, A.L. Leptomeningeal Carcinomatosis. Medscape Jan 2010. http://boards.medscape.com/forums?128@46.llrqaDqDLlE@.29f9cbd4!comment=1
10. Kokkoris, C.P. Leptomeningeal Carcinomatosis: how does cancer reach the pia-arachnoid? Cancer, 1983, 51, 154-160.
11. Olson, M.E.; Chernik, N.L.; Posner, J.B. Infiltration of the leptomeninges by systemic cancer A clinical and pathologic study. Arch. Neurol., 1974, 30, 122-137.
12. Drappatz, J.; Batchelor, T.T. Leptomeningeal Metastasis. ASCO Educational Book, 2009, 100-105.
13. Balm, M.; Hammack, J. Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch. Neurol., 1996, 53, 626-632.
14. Wolfgang, G.; Marcus, D. Leptomeningeal carcinomatosis: clinical syndrome in different primaries. J. Neurooncol., 1998, 38, 103-110.
15. Chamberlain, M.C. Neoplastic meningitis. Neurologist, 2006, 12, 179-187.
16. Chamberlain, M.C.; Kormanik, P.R. Carcinomatous meningitis secondary to breast cancer: Predictors of response to combined modality therapy. J. Neurooncol., 1997, 35, 55-64.
17. Chamberlain, M.C. Neoplastic meningitis. Oncologist, 2008, 13, 967-977.
18. Chamberlain, M.C., Neoplastic meningitis. J. Clin. Oncol., 2005, 23, 3605-3613.
19. Galoin, S.; Daste, G.; Apoil, P.A. Polymerase chain reaction on cerebrospinal fluid cells in the detection of leptomeningeal involvement by B-cell lymphoma and leukaemia: a novel strategy and its implications. Br. J. Haematol., 1997, 99, 122-130.
20. Fischer, L.; Martus, P.; Weller, M. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology, 2008, 71, 1102-1108.
21. Hug, A.; Storch-Hagenlocher, B.; Haas, J. Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J. Neurol. Sci., 2004, 219, 83-88.
22. Bromberg, J.E.; Breems, D.A.; Kraan, J. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology, 2007, 68, 1674-1679.
23. Aroney, R.S.; Dalley, D.N.; Chan, W.K. Meningeal carcinomatosis in small cell carcinoma of the lung. Am. J. Med., 1981, 71, 26-32.
24. Kaplan, J.G.; DeSouza, T.G.; Farkash, A. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumours, lymphomas, and leukemias. J. Neurooncol., 1990, 9, 225-229.
25. Reuler, J.B.; Meier, D. Leptomeningeal carcinomatosis with normal CSF features. Arch. Intern. Med., 1979,139, 237-238.
26. Twijnstra, A.; Ongerboer de Visser, B.W.; van Zanten, A.P. Diagnosis of leptomeningeal metastasis. Clin. Neurol. Neurosurg., 1987, 89, 79-85.
27. Glass, J.P.; Melamed, M.; Chernik, N.L. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology, 1979, 29, 1369-1375.
28. Chamberlain, M.C. Cytologically negative carcinomatous meningitis: usefulness of CSG biochemical markers. Neurology, 1998, 50, 1173-1175.
29. Twijnstra, A.; Ongerboer de Visser, B.W.; van Zanten, A.P.; Hart, A.A.; Nooyen, W.J. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J. Neurooncol., 1989, 7, 57-63.
30. Boehme, V.; Zeynalova, S.; Kloess, M.; Loeffler, M.; Kaiser, U.; Pfreundschuh, M. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma. A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann. Oncol., 2007, 18, 149-157.
31. Yoshida, S.; Morii, K. Intrathecal chemotherapy for patients with meningeal carcinomatosis. Surg. Neurol., 2005, 63, 52-55.
32. Chamberlain, M.C. Neoplastic meningitis. Neurologist, 2006, 12, 179-187.
33. Chamberlain, M.C.; Glantz, M.; Groves, M.D.; Wilson, W.H. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determine benefit of treatment. Sem. Oncol., 2009, 36 (suppl 2), S35-S45.
34. Chamberlain, M.C.; Sandy, A.D.; Press, G.A. Leptomeningeal metastasis: A comparison of gadolinium-enhanced MR and contrast- enhanced CT of the brain. Neurology, 1990, 40, 435-438.
35. Schumacher, M.; Orszagh, M. Imaging techniques in neoplastic meningiosis. J. Neurooncol., 1998, 38, 111-120.
36. Sze, G.; Soletsky, S.; Bronen, R. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJR Am. J. Roentgenol., 1989, 153, 1039-1049.
37. Schuknecht, B.; Huber, P.; Büller, B. Spinal leptomeningeal neoplastic disease. Evaluation by MR, myelography and CT myelography. Eur. Neurol., 1992, 32, 11-16.
38. Chamberlain, M.C. Comparative spine imaging in leptomeningeal metastases. J. Neurooncol., 1995, 29, 233-238.
39. Sze, G.; Soletsky, S.; Bronen, R. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am. J. Nucl. Radiol., 1989, 10, 965-975.
40. Chamberlain, M.C.; Sandy, A.D.; Press, G.A. Leptomeningeal metastasis: a comparison of gadolinium enhanced MR and contrast enhanced CT of the brain. Neurology, 1990, 40, 435-438.
41. Freilich, R.J.; Krol, G.; DeAngelis, L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol., 1995, 38, 51-57.
42. Krol, G.; Sze, G.; Malkin, N.M. MR of cranial and spinal meningeal carcinomatosis: comparison with CT and myelography. Am. J. Roentgenol., 1988, 151, 583-588.
43. Zeiser, R.; Burger, J.A.; Bley, T.A.; Windfuhr-Blum, M.; Schulte-Monting, J.; Behringer, D.M. Clinical follow-up indicates different accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis. A single centre experience. Br. J. Haematol., 2004, 124, 762-768.
44. Chamberlain, M.C.; Glantz, M.; Groves, M.D.; Wilson, W.H. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin. Oncol., 2009, 36 (4 Suppl 2). 2, S35-S45.
45. Chamberlain, M.C. Radioisotope CSF flow studies in leptomeningeal metastases. J. Neurooncol., 1998, 38, 135-140.
46. Glantz, M.J.; Hall, W.A.; Cole, B.F. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 1995, 75, 2919-2931.
47. Chamberlain, M.C. Comparative spine imaging in leptomeningeal metastases. J. Neurooncol., 1995, 23, 233-238.
48. Grossman, S.A.; Trump, D.L.; Chen, D.C. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am. J. Med., 1982,73, 641-647.
49. DeAngelis, L.M. Current diagnosis and treatment of leptomeningeal metastasis. J. Neurooncol., 1998, 38, 245-252.
50. Hildebrand, J. Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood. J. Neurooncol., 1998, 38, 193-198.
51. Gleissner, B.; Chamberlain, M.C. Neoplastic meningitis. Lancet Neurol., 2006, 5, 443-452.
52. Chamberlain, M.C.; Kormanik, P.A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch. Neurol., 1997, 54, 1364-1368.
53. Chamberlain, M.C. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology, 2003, 60, A17-18.
54. Ghersi-Egea, J.F.; Leininger-Muller, B.; Cecchelli, R.M.; Fenstermacher, J.D. Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol. Lett., 1995, 82, 645-653.
55. Leptomeningeal Metastases v.1.2010, National Comprehensive Cancer Network.
56. Rogers, L.R.; Chamberlain, M.C.; Glantz, M.J. Evidence-based review of intrathecal chemotherapy outcome of patients with leptomeningeal metastasis. ASCO Annual Meeting Proceedings, 2006, Vol. 24(18S) (suppl), p. 1529.
57. Glantz, M.J.; LaFollette, S.; Jaeckle, K.A.; Shapiro, W.; Swinnen, L.; Rozental, J.R.; Phuphanich, S.; Rogers, L.R.; Gutheil, J.C.; Batchelor, T.; Lyter, D.; Chamberlain, M.; Maria, B.L.; Schiffer, C.; Bashir, R.; Thomas, D.; Cowens, W.; Howell, S.B. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol., 1999, 17, 3110-3116.
58. Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L., Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, GB.; Cole, BF.; Howell, S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res., 1999, 5, 3394-3402.
59. Rudnicka, H.; Niwińska, A.; Murawska, M. Breast cancer leptomeningeal metastasis. The role of multimodality treatment. J. Neurooncol., 2007,84, 57-62.
60. Boogerd, W.; van den Bent, M.J.; Koehler, P.J.; Heimans, J.J.; van der Sande, J.J.; Aaronson, N.K.; Hart, A.A.; Benraadt, J.; Vecht, Ch.J. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. J. Cancer, 2004, 40, 2726-2733.
61. Siegal, T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J. Neurooncol., 1998, 38, 151-157.
62. Giannone, L.; Greco, F.A.; Hainsworth, J.D. Combination intraventricular chemotherapy for meningeal neoplasia. J. Clin. Oncol., 1986, 4, 68-73.
63. Hitchins, R.N.; Bell, D.R.; Woods, R.L. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. Oncol., 1987, 5, 1655-1666.
64. Grossman, S.A.; Finkelstein, D.M.; Ruckdeschel, J.C. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J. Clin. Oncol., 1993, 11, 561-569.
65. Glantz, M.J.; Hall, W.A.; Cole, B.F. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 1995, 75, 2919-2931.
66. Blaney, S.M.; Balis, F.M.; Berg, S.; Arndt, C.A.; Heideman, R.; Geyer, J.R.; Packer, R.; Adamson, P.C.; Jaeckle, K.; Klenke, R.; Aikin, A.; Murphy, R.; McCully, C.; Poplack, D.G. Intrathecal, mafosfamide: a preclinical pharmacology and phase I trial. J. Clin. Oncol., 2005, 23, 1555-1563.
67. Blaney, S.M.; Heideman, R.; Berg, S. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J. Clin. Oncol., 2003, 21, 143-147.
68. Chamberlain, M.C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer, 2002, 94, 2675-2680.
69. Chamberlain, M.C. World Federation of Neuro-Oncology Second Quadriennal Meeting and the Sixth Meeting for the European Association of Neuro-Oncology, 2005 May 5-8, Edimburgh, UK.
70. Rubenstein, J.L.; Combs, D.; Rosenberg, J.; Levy, A.; McDermott, M.; Damon, L.; Ignoffo, R.; Aldape, K.; Shen, A.; Lee, D.; Grillo-Lopez, A.; Shuman, M.A. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 2003, 101, 466-468.
71. Rubenstein, J.L.; Fridlyand, J.; Abrey, L.; Shen, A.; Karch, J.; Wang, E.; Issa, S.; Damon, L.; Prados, M.; McDermott, M.; O'Brien, J.; Haqq, C.; Shuman, M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol., 2007, 25, 1350-1356.
72. Allison D. L.; Glantz M.; Werner T. L.; Kirkegaard S. L.; Murdock K.; Jensen, R. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. J. Clin. Oncol., 2009, 27, 15s, (suppl; abstr 2066).
73. Coakham, H.B.; Kemshead, J.T. Treatment of neoplastic meninigitis by targeted radiation using 131I-radiolabelled monoclonal antibodies. J. Neurooncol., 1998, 38, 225-232.
74. Chamberlain, M.C.; Kormanik, P.A.; Barba, D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J. Neurosurg., 1997, 87, 694-699.
75. Fizazi, K.; Asselain, B.; Vincent-Salomon, A. Meningeal carcinomatosis in patients with breast carcinoma clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer, 1996, 77, 1315-1323.
76. Lassman, A.B.; Abrey, L.E.; Shah, G.D. Systemic high-dose intravenous methotrexate for central nervous system metastases. J. Neurooncol., 2006, 78, 255-260.
77. Glantz, M.J.; Cole, B.F.; Recht, L. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol., 1998, 16, 1561-1567.
78. Lopez, J.A.; Nassif, E.; Vannicola, P.; Krikorian, J.G.; Agarwal R.P. Central nervous system pharmacokinetics of highdose cytosine arabinoside. J. Neurooncol., 1985, 3, 119-124.
79. Slevin, M.L.; Piall, E.M.; Aherne, G.W.; Harvey, V.J.; Johnston, A.; Lister, T.A. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J. Clin. Oncol., 1983,1, 546-551.
80. DeAngelis, L.M.; Kreis, W.; Chan, K.; Dantis, E.; Akerman, S. Pharmacokinetics of ara-C and ara-U in plasma and CSF after highdose administration of cytosine arabinoside. Cancer Chemother. Pharmacol., 1992, 29, 173-177.
81. Sutoh, H.; Yamauchi, T.; Gotoh, N.; Sugiyama, M.; Ueda, T. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. Anticancer Res., 2003, 23, 5037-5042.
82. Jayson, G.C.; Howell, A. Carcinomatous meningitis in solid tumours. Ann. Oncol., 1996, 7, 773-786.
83. Grossman, S.A.; Krabak, U.S. Leptomeningeal carcinomatosis. Cancer Treat Rev., 1999, 25, 103-109.
84. Giglio, P.; Tremont-Lukats, I.W.; Groves M.D. Response of neoplastic meningitis from solid tumors to oral capecitabine. J. Neurooncol., 2003, 65, 167-172.
85. Ekenel, M.; Hormigo, A.M.; Peak, S.; DeAngelis, L.M.; Abrey, L.E. Capecitabine therapy of central nervous system metastases from breast cancer. J. Neurooncol., 2007, 85, 223-227.
86. Tham, Y.L.; Hinckley, L.; The, B.S.; Elledge, R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case treport. Clin. Breast Cancer, 2006, 7, 164-166.
87. Davis, T.H.; Fadul, C.E.; Glantz, M.J. Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report. ASCO Annual Meeting Proceedings, 2003, Vol. 22(115a) (suppl), p. 460.
88. Friedman, H.S. Temozolomide in early stage of newly diagnosed malignant glioma and neoplastic meningitis. Sem. Oncol., 2000, 27, 35-40.
89. Ostermann, S.; Csajka, C.; Buclin, T. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res., 2004, 10, 3728-3736.
90. Choong, N.W.; Dietrich, S.; Seiwert, T.Y. Gefitinib response of erlotinib-refractory lung cancer involving meninges. Role of EGFR mutation. Nat. Clin. Pract. Oncol., 2006, 3, 50-57.
91. Kanaji, N.; Bandoh, S.; Nagamura, N.; Kushida, Y.; Haba, R.; Ishida, T. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Intern. Med., 2007, 46, 1651-1655.
92. Togashi, Y.; Masago, K.; Fukudo, M.; Terada, T.; Fujita, S.; Irisa, K.; Sakamori, Y.; Kim, Y.H.; Mio, T.; Inui, K.; Mishima, M. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of nonsmall cell lung cancer. J. Thorac. Oncol., 2010, 5, 950-955.
93. Groves, M.D.; Hess, K.R.; Puduvalli, V.K. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J. Neurooncol., 2009, 94, 229-234.
94. Stockhammer, G.; Poewe, W.F.; Burgstaller, S.F. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology, 2000, 54, 1670-1676.
95. Herrlinger, U.; Wiendl, H.; Renninger, M.; Forschler, H.; Dichgans, J.; Weller, M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br. J. Cancer., 2004, 91, 219-224.
96. Kim, L.; Glantz, M.J. Neoplastic meningitis. Curr. Treat Options Oncol., 2001, 2, 517-527.
97. Shapiro, W.R.; Johanson, C.E.; Boogerd, W. Treatment Modalities for Leptomeningeal Metastases. Semin. Oncol., 2009, 36 (Suppl 2), S46-S54.
98. Groves, M.D. New strategies in the management of leptomeningeal metastases. Arch. Neurol., 2010, 67, 305-312.
99. Shapiro, W.R.; Schmid, M.; Glantz, M. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J. Clin. Oncol., 2006, 24(suppl 6), abstract 1528.